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Structural basis of metallo-b-lactamase,
serine-b-lactamase and penicillin-binding protein
inhibition by cyclic boronates
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b-Lactamases enable resistance to almost all b-lactam antibiotics. Pioneering work revealed
that acyclic boronic acids can act as ‘transition state analogue’ inhibitors of nucleophilic
serine enzymes, including serine-b-lactamases. Here we report biochemical and biophysical
analyses revealing that cyclic boronates potently inhibit both nucleophilic serine and
zinc-dependent b-lactamases by a mechanism involving mimicking of the common
tetrahedral intermediate. Cyclic boronates also potently inhibit the non-essential penicillin-
binding protein PBP 5 by the same mechanism of action. The results open the way for
development of dual action inhibitors effective against both serine- and metallo-b-lacta-
mases, and which could also have antimicrobial activity through inhibition of PBPs.
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T
he b-lactamase-catalysed hydrolysis of b-lactam antibiotics
(BLAs) is of central importance in antibiotic resistance1.
b-Lactam-based inhibitors (for example clavulanic acid) of
the Class A serine-b-lactamases (SBLs) are widely used in
combination with penicillins2. Recently, avibactam, an inhibitor
of Class A, C and some Class D SBLs, has been introduced for
clinical use in combination with a cephalosporin1. Though not a
b-lactam, avibactam is susceptible to b-lactamase-catalysed
hydrolysis1. In contrast to SBLs, there are no clinically useful
inhibitors of the Class B zinc-dependent metallo-b-lactamases
(MBLs), which are of growing concern as a cause of antibiotic
failure. With the exception of the monobactams, MBLs catalyse
the hydrolysis of all b-lactam families including penicillins,
cephalosporins, carbapenems and SBL inhibitors3.
SBLs and the penicillin-binding protein (PBP) targets of the
b-lactams are evolutionarily and mechanistically related; as a
consequence, several b-lactam classes, for example, carbapenems,
can inhibit both SBLs and PBPs4. MBLs, however, are
mechanistically and structurally distinct, and constitute a
heterogeneous group2. The requirement for clinically useful
inhibition of a broad spectrum of clinically relevant MBL
subfamilies (NDM, IMP, VIM, SPM), which differ in the loops
surrounding their active site, makes them challenging medicinal
chemistry targets5.
Since many bacteria have acquired both SBL- and
MBL-mediated resistance1, we are interested in identifying
dual action MBL/SBL inhibitors. Very few potent inhibitors
(IC50o1mM) targeting SBLs, MBLs and/or PBPs have been
developed. Since transient oxyanionic species (for example the
‘tetrahedral intermediate’ of SBLs) produced by nucleophilic attack
onto the b-lactam carbonyl are likely common to SBL- and
MBL-catalysed b-lactam hydrolysis3,6, we reasoned analogues of
this intermediate may provide the desired dual action-BL
activity. While such ‘tetrahedral intermediate’ analogues are well-
characterized for nucleophilic enzymes, including PBPs and SBLs2,
they have not been widely described for metallo-hydrolases. The
observation of MBL inhibition by triﬂuoromethyl ketones7 is
evidence that mimicking a tetrahedral intermediate may also be
useful for the inhibition of MBLs. Since acyclic boronic acids, are
established as SBL/PBP inhibitors1 (the SBL inhibitor, RPX7009
(ref. 1), is in clinical trials), we screened various boronic acids,
including some reported to be SBL/PBP inhibitors, for inhibition of
the NDM-1 MBL. Interestingly, cyclic boronates, but not the
acyclic boronic acids, manifested potent MBL inhibition. We
therefore synthesized and tested additional boronic acids, including
compounds (2, 4 and 5) described in the patent literature as
b-lactamase inhibitors8 and novel derivatives 1 and 3 (designed
using modeling).
We demonstrate through biochemical, biophysical and cellular
evidence that cyclic boronates are potent inhibitors of both
SBLs and MBLs. Interestingly, we also found that the cyclic
boronates inhibit the PBP targets of the BLAs. High-resolution
crystallographic analyses reveal the proposed mechanism of
action. The cyclic boronates act as ‘transition state analogues’ for
both ‘serine’ and ‘metallo’ enzymes and therefore represent a
promising strategy for combating antibiotic resistance.
Results
MBL inhibition by cyclic boronates. Using a ﬂuorogenic assay
for MBLs9, we screened the cyclic boronates (Fig. 1) against a
representative panel of clinically relevant B1 subfamily MBLs,
including IMP-1 (Imipenemase-1), VIM-2 (Verona-Integron-
Encoded MBL-2), NDM-1 (New Delhi MBL-1), SPM-1
(Sa˜o Paulo MBL-1) and the model MBL, BcII from Bacillus
cereus2. The results imply that cyclic boronates with an aromatic
side chain, positioned analogously to the 6b/7b side chains of the
penicillins/cephalosporins, are potent inhibitors of B1 MBLs
(for example, pIC50 values for 5 range from 8 to 9 against VIM-
2 and NDM-1; Table 1). In support of these ﬁndings, 19F-protein
NMR studies, employing site-selective labelling of M67C NDM-1
with 1,1,1-triﬂuoro-3-bromo acetone10, reveal tight binding of 2 to
the active site of the NDM-1 MBL (Supplementary Fig. 1).
In vitro inhibition of MBLs by the tested cyclic boronates
yielded the following rank order of potency: VIM-24
NDM-14BcII4IMP-14SPM-1 (Table 1). As SPM-1 (a ‘hybrid’
enzyme with properties of both the B1/B2 MBL subfamilies11) was
inhibited least strongly (IC50 13–36mM), we investigated inhibition
of Aeromonas hydrophilia CphA12 as a representative of the
mono-Zn(II) B2 MBL subfamily and observed similar inhibition
potency (high mM range, Table 1), suggesting that the tested cyclic
boronates may be less potent against B2 MBLs. Overall, these data
identify 2 and 5 as highly potent inhibitors of VIM-2 and NDM-1,
respectively, the most widely distributed members of the clinically
important B1 subfamily (Table 1).
SBL and PBP inhibition by cyclic boronates. We then used
ﬂuorogenic assays9 to measure the potency of the cyclic
boronates against clinically relevant Class A and Class D
SBLs, including TEM-1 (Class A) and OXA-10 (Class D)13.
All of the compounds tested were potent TEM-1 inhibitors
(IC50 6-0.3 nM, Table 1) and compounds with saturated
side chains (1 and 3) manifested IC50 valueso1mM against
OXA-10 (Table 1). Although our initial objective was to identify
and characterize compounds potent against both MBLs and
SBLs, the observed potency of the cyclic boronates versus
SBLs motivated us to also investigate their potential for inhibition
of a mechanistically-related PBP.14 PBP 5 (dacA) from Escherichia
coli, which is a non-essential PBP15, was potently inhibited by all
tested cyclic boronates (residual activityo1% at 10mM; IC50 for 2,
1.7 nM). We also tested the essential PBP 3 from Pseudomonas
aeruginosa at 100mM against the cyclic boronates, but no inhibition
was detected (Table 1). These results reveal the potential for cyclic
boronates to act as broad-spectrum inhibitors of SBLs and MBLs
with activity against, at least some, PBPs.
Pathogen susceptibility to cyclic boronate. Since 2 was a potent
inhibitor of all three enzyme classes in vitro, we next tested its
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Figure 1 | Structures of cyclic boronates used in our work.
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activity against bacterial cells (the Gram-negative pathogens
E. coli and Klebsiella pneumoniae) in antimicrobial susceptibility
assays (Table 2). 2 was evaluated against multiple strains of
both organisms and, alone and in combination with the
carbapenem meropenem, against recombinant K. pneumoniae16
and previously described K. pneumoniae and E. coli strains of
clinical origin.17 These strains all carry the NDM-1 MBL,
together with multiple SBLs of different classes17. 2 alone did
not display antibacterial activity against any of the strains
tested at concentrations up to 128mgml 1 (for E. coli
ATCC 25922 and K. pneumoniae NCTC 5055, data not
shown). The minimal inhibitory concentrations (MICs)
determined for NDM-1-expressing K. pneumoniae Ecl8 in the
presence of compound 2 at concentrations ranging from 0.5 to
64 mgml 1 demonstrated a dose-dependent increase in
susceptibility as the concentration of 2 increased (Supple-
mentary Table 1). For all the strains producing NDM-1, co-
administration with 2 reduced the MIC of meropenem. Clear
reductions in meropenem MIC were observed at 10 mgml 1 2.
At a concentration of 25mgml 1, 2 brought the meropenem
MIC into the susceptible range (MICo8mgml 1) for
recombinant K. pneumoniae strain Ecl8 and its DramR mutant
derivative (which has reduced envelope permeability through
reduced porin and increased efﬂux pump production) when both
are producing NDM-1. Neither 1 nor 2 showed cytotoxicity in
human HEK293 cells when administered at concentrations up to
100mM (Supplementary Fig. 2).
Structural analysis of cyclic boronate binding to BcII and VIM-2.
We then investigated the mechanism of MBL inhibition by 2 using
X-ray crystallography. We obtained high-resolution structures for
VIM-2 and BcII in complex with 2 to 1.5Å and 1.9Å resolution,
respectively (Supplementary Figs 3–6). In both these structures, the
electron density for the inhibitor clearly deﬁnes the geometry of the
boron as tetrahedral (sp3).
For the B1 subfamily MBLs, b-lactam hydrolysis is proposed to
proceed via nucleophilic attack of a hydroxide ion onto the
b-lactam carbonyl; in ground state structures, this hydroxide
bridges the two active site zinc ions (Zn1 and Zn2)17. A transient
tetrahedral oxyanionic species (Fig. 2a) is formed that reacts to
give a Zn1-bound carboxylate and a, sometimes detectable,
intermediate18 in which the negatively charged b-lactam-derived
nitrogen coordinates to Zn2; protonation of this intermediate is
required for product release. The mode of binding of 2 observed
here, in which both boron-bound oxygen atoms participate in
bidentate coordination of the Zn1 ion, most closely resembles
that predicted for the tetrahedral oxyanion formed during
b-lactam hydrolysis, with the implication that these inhibitors
act as mimics of this state (Fig. 2b,c).
The structures of both BcII and VIM-2 in complex with 2
reveal binding modes similar in some key aspects to those
observed for complexes of B1 MBLs with hydrolysed b-lactams,
in particular for a ring-opened cephalosporin intermediate19
(Fig. 2d). First, one oxygen atom of the inhibitor C-3
carboxylate coordinates to Zn2; the other carboxylate oxygen
Table 1 | In vitro screening of cyclic boronates.
IC50 (lM)/pIC50/s.e. logIC50*
1 2 3 4 5
BcII 7.27/5.1/0.052 0.30/6.5/0.032 0.96/6.0/0.041 0.52/6.2/0.194 1.14/5.9/0.029
VIM-2 0.051/7.3/0.034 0.003/8.5/0.058 0.011/7.9/0.028 0.014/7.8/0.044 0.002/8.7/0.1144
IMP-1 1.44/4.6/0.116 1.00/5.0/0.089 1.50/4.5/0.112 1.21/4.7/0.127 1.41/4.5/0.127
NDM-1 2.04/5.7/0.028 0.029/7.5/0.020 0.687/6.1/0.068 0.04/7.4/0.021 0.004/7.4/0.051
SPM-1 24.1/4.6/0.162 16.7/4.7/0.103 16.0/4.8/0.093 13.9/4.8/0.172 36.3/4.4/0.207
CphA 4.42/5.3/0.159 4100/44/- 20.85/4.68/0.23 4100/44/- 4100/44/-
TEM-1 0.001/8.9/0.447 0.003/8.4/0.033 0.002/8.5/0.030 0.0003/9.4/0.46 0.006/8.1/0.007
OXA-10 0.33/6.4/0.019 5.1/5.2/0.020 0.83/6.0/0.012 2.26/5.6/0.028 12.7/4.9/0.0258
PBP 5 NT 0.0016/8.7/0.06 NT NT NT
PBP 3 NI NI NI NI NI
MBL, metallo-b-lactamase; NI, no inhibition at 100mM; NT, not tested; PBP, penicillin-binding protein; SBL, serine-b-lactamase.
*Errors were calculated as s.d. of at least three independent measurements. Note compounds 2, 4 and 5 were identiﬁed in the patent literature8.
IC50/pIC50 values of cyclic boronates against a panel of MBLs, SBLs and PBPs (see Supplementary Methods for experimental details).
Table 2 | In vitro cell-based screening of cyclic boronate 2.
Bacterial strain Genotype (b-lactamases) 2 MIC
(lgml 1)
Meropenem MIC
(lgml 1)
Meropenem MIC (lgml 1)
(10lg ml 1 2)
Meropenem MIC (lgml 1)
(25lg ml 1 2)
K. pneumoniae Ecl8
pSU18
blaSHV-1 4128 r0.25 r0.25 r0.25
K pneumoniae Ecl8
DramR pSU18
blaSHV-1 4128 r0.25 r0.25 r0.25
K. pneumoniae Ecl8
pSU18:NDM-1
blaSHV-1; blaNDM- 1 4128 4128 8 4
K pneumoniae Ecl8
DramR pSU18:NDM-1
blaSHV-1; blaNDM- 1 4128 4128 16 2
E. coli IR10 blaDHA-1; blaCTX-M-15; blaTEM-1;
blaOXA-1; blaNDM- 1
4128 128 8 2
E. coli IR60 blaDHA-1; blaCTX-M-15; blaTEM-1;
blaOXA-1; blaNDM- 1
4128 64 16 16
K. pneumoniae IR8 blaSHV-1; blaDHA-1; blaCTX-M-15;
blaTEM-1; blaNDM-1
4128 128 32 16
MIC, minimal inhibitory concentration.
Testing the potency of 2 towards resenzitization of meropenem activity using well-characterized and clinically derived strains.
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interacts with Lys224 (NDM-1 and BcII) or Arg228 (VIM-2) by
hydrogen-bonding/electrostatic interactions. These interactions
are analogous to those with hydrolysed b-lactams where the
C-3/C-4 carboxylate (of penicillins/cephalosporins, respectively)
binds Zn2 and Lys224 (BcII and NDM-1) or Arg228 (in the VIM
family) (Fig. 2b)3,19. Second, both the BcII and VIM-2 structures
reveal that in the MBL-active sites the bicyclic phenyl-boronate
ring of 2 is very similarly positioned to the cephalosporin
dihydrothiazine ring (or analogous penicillin/carbapenem derived
rings)19, with both being positioned to make hydrophobic
interactions with the conserved Trp87 and Phe61 residues.
Notably, the ‘endocyclic’ boronate ester oxygen of 2 coordinates
to Zn2, mimicking the coordination of the cephalosporin-derived
dihydrothiazine ring nitrogen in the anionic intermediate. Third,
the binding mode of the side chain of 2 is analogous to that of the
7b side chain of cephalosporins (Fig. 2b,d), in that the carbonyl
oxygen of the 7b-acetamido group of the side chain of 2 and the
cephalosporin intermediate are both positioned to hydrogen bond
with the main chain NH group of residue-119 (Ala (BcII), Asp
(VIM-2) or Glu (NDM-1)). Fourth, as observed in a complex of
NDM-1 with a cephalosporin-derived intermediate, the C-6
carboxylate arising from b-lactam hydrolysis is positioned to
coordinate Zn1 and hydrogen bond via one of its oxygen atoms to
the Asn233 side chain. Fifth, binding of the two ‘exocyclic’
boron-bound oxygens/hydroxides mimics the binding modes
proposed for the two oxygens in the oxyanion intermediate. The
pro-(S) boron-bound exocyclic oxygen coordinates with Zn1 and
is positioned to hydrogen bond with Asn233 and the NH of the
acetamido side chain. In MBL catalysis, the highly conserved
Asn233 side chain is proposed to stabilize the oxyanionic
intermediate via hydrogen bonding with the lactam
carbonyl-derived oxygen. 20 (The structures suggest that
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Figure 2 | Mode of action of metallo-b-lactamases and binding mode of cyclic boronates. (a) Outline mode of action of MBLs showing proposed
intermediates. (b,c) Views from structures obtained by co-crystallization of 2 with BcII (b) and VIM-2 (Chain A) (c). Note the relative position of Trp87 is
rotated byB180 compared with its position in structures of BcII and VIM-2 without inhibitor; in the case of VIM-2, Trp87 interacts with the cyclic boronate
via a water molecule. (d) The overlay compares the binding modes of 2 and hydrolysed cefuroxime in complex with NDM-1 (PDB ID: 4RL2)). (e) Key active
site interactions made by the cyclic boronates.
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hydrogen bonding to the substrate side chain is also involved in
stabilizing the oxyanion). The pro-(R) boron-bound exocyclic
oxygen bridges Zn1 and Asp120, mimicking the proposed position
of the hydroxide-derived oxygen in the oxyanion intermediate.
Overall, the complexes of 2 with VIM-2 and BcII reveal that
binding of the cyclic boronates closely mimics that proposed for
the high-energy tetrahedral intermediate in MBL catalysis21
(Fig. 2a,e), both in terms of structure and bonding.
Structural analysis of cyclic boronate binding to OXA-10. We
then investigated the binding mode of the cyclic boronates to
SBLs, by determining a high-resolution crystal structure of
the Class D b-lactamase OXA-10 in complex with 1 (1.5 Å
resolution; Supplementary Fig. 3,7). OXA-10 requires a carba-
mylated active site lysine (KCX70) for catalysis22 (Fig. 3a), which
was observed in the OXA-10:1 complex structure (Fig. 3b,
Supplementary Fig. 3). Inspection of maps (Supplementary Fig. 3)
reveals continuous electron density connecting the inhibitor
boron atom with the terminal hydroxyl group of the nucleophilic
serine (Ser67) and provides clear evidence for a tetrahedral boron
atom, contrasting with the planar geometry of the carbonyl
carbon atoms of b-lactam acyl-enzyme complexes
(Supplementary Fig.8). The structure of the complex with 1
thus represents a covalent species that better resembles the ‘ﬁrst’
tetrahedral intermediate, which is involved in acyl-enzyme
formation, rather than the acyl-enzyme itself (Fig. 3a). Hence,
analogous to our structural observations with the VIM-2 and BcII
MBLs (above), the OXA-10:1 complex structure reveals that 1
mimics the mechanistically important tetrahedral oxyanion that
is transiently present on the hydrolytic pathway. Furthermore,
comparison of the OXA-10:1 complex with that of a penicillin
(benzylpenicillin) bound to a ‘deacylation-deﬁcient’ OXA-10
(K70C variant)23 reveals strikingly related overall binding modes.
In particular, the carboxylate of 1 and the C-3 carboxylate of
penicillin (Fig. 3b,c) are both positioned to interact with Arg250,
while the acetamido group of 1 and the benzylpenicillin C6 amide
group are analogously positioned to hydrogen bond with the
main chain carbonyl of Phe208. Finally, the endocyclic boronate
ester oxygen of 1 and the b-lactam-derived nitrogen (from the
penicillin thiazolidine ring) are both positioned to hydrogen bond
with Ser115.
Structural analysis of cyclic boronate binding to PBP 5. We
then carried out crystallographic studies to investigate the binding
mode of the cyclic boronates to PBPs (Fig. 4a), by solving a crystal
structure of PBP 5 in complex with 2 (2.5Å resolution;
Supplementary Fig. 3,9). Comparison of the PBP 5:2 complex
structure with reported PBP5 structures reveals that the fold of
Domain 1 (aa 3–262) of PBP 5, which contains the transpeptidase/
penicillin-binding active site, is very similar in both structures
(Supplementary Fig. 10); However, clear differences are observed
in the position of Domain 2 (aa 263–356).
To date, all reported PBP 5 structures with ligands (substrate-
like peptide boronic acids or acyl-enzyme complexes with
penicillins, cephalosporins or carbapenems) manifest weak or
absent density for the C6 or C7 side chains of the penicillins or
cephalosporins, respectively, or the C30 cephalosporin side
chain24–26. Importantly, for the PBP 5:2 complex, inspection of
the experimental map revealed clear electron density for the
whole inhibitor molecule (Supplementary Fig. 3).
Comparison of the PBP 5:2 complex with a PBP 5:cloxacillin
acyl-enzyme structure25 reveals similar binding modes for the
E + S SE EI EP E + P
N
S
H
N
O
R
CO2–
O R'
Substrate (S)
Enzyme (E)
+
N
S
CO2–
Product (P)
NH
O
OH
O
R
R'+
Ser70
OH
Base
B
H2O
(H)N
S
CO2–
R'
Acyl-enzyme
complex
(EI)
N
S
H
N
CO2–
R'
Ser70
O
O
O
R NH
O
O
O
R
Ser70 (H)N
S
CO2–
R'
NH
O
O
R
Ser70
HO
HO
OXA-10
Trp102
Met99
KCX70 Ser67
Ser67
Gly207
Phe208 Arg250
Overlay
B O
OHO
H
N
O
HOO
Ser67
Tetrahedral
HN
S
H
N
O
OH
O
O
O
Ser67
Trigonal
From benzylpenicillin
Serine-β-lactamase catalysis
Tetrahedral
intermediate 1
(EI1)
Tetrahedral
intermediate 2
(EI2)
–
a
b c
Figure 3 | Mode of action of serine-b-lactamases and binding mode of cyclic boronates. (a) Outline mode of action of SBLs. (b) View from a structure
obtained by co-crystallization of 1 with OXA-10 (Chain A) revealing the binding mode of cyclic boronates to SBLs. (c) The overlay compares the binding
modes of 1 and hydrolysed benzylpenicillin in complex with OXA-10 (PDB ID: 2WGI).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12406 ARTICLE
NATURE COMMUNICATIONS | 7:12406 |DOI: 10.1038/ncomms12406 |www.nature.com/naturecommunications 5
two compounds in the active site (Fig. 4b,c), including with
respect to (i) interactions with the conserved active site motifs
(SxxK and SxN), the conformations of which overlap almost
exactly in the two structures; (ii) conservation of the predicted
active site hydrogen-bonding network; and (iii) the same
bidendate interaction of Arg248 with the carboxylate of 2 or
the C-3 penicillin carboxylates25.
Three other features of the PBP 5:2 complex structure are of
interest. First, the conserved O-like loop that is conserved in
PBPs and Class A SBLs adopts a ‘closed’ position (that is,
closer to the active site) when complexed with 2, compared
with previously published apo- or acyl-enzyme structures
(Supplementary Fig. 11). Interestingly, in the structure of
PBP 5 complexed with substrate-like peptide boronic acid, the
O-like loop was reﬁned in dual conformations, one similar
to that observed in the PBP5:2 structure and one similar
to the apo- and the acyl-enzyme structures (Supplementary
Fig. 11). Second, compared with the previous acyl-enzyme
structures, in the structure with 2, His216 moves 43.5 Å to
interact with the carboxylate of 2, which is analogous to
binding of the penicillin C-3 carboxylate, implying an
important role for this residue in substrate binding. Third,
the ‘bridging’ water molecule that is proposed to polarize
and orient the hydrolytic water molecule for hydrolysis in the
acyl-enzyme complex was absent in the PBP 5:2 structure
(Supplementary Fig. 12).
Discussion
The combined results reveal that cyclic boronates act as dual
action inhibitors of SBLs and MBLs by mimicking a common
high-energy tetrahedral intermediate; they also reveal that cyclic
boronates can potently inhibit some PBPs via the same
mechanism. Cyclic boronates thus represent a promising line of
investigation not only for the protection of BLAs from both MBLs
and/or SBLs, but also for direct inhibition of PBPs. The structural
results presented here will aid in the development of optimized
cyclic boronates, possibly with activity against the essential PBPs.
The demonstrated utility of a single compound (class) to
simultaneously inhibit both nucleophilic serine- and metallo-
hydrolases is also of interest in other drug discovery ﬁelds,
including cancer, where it may be desirable to inhibit different
classes of functionally related proteases27. Notably, the cyclic
boronates, but not acyclic boronic acids, were potent MBL
inhibitors, suggesting that cyclic, or otherwise conformationally
constrained transition state analogues, either employing boronates
or related functional groups that mimic intermediates (for example,
ﬂuoromethyl ketones) may represent a generally productive route
towards simultaneous inhibition of mechanistically different types
of hydrolases by the same compound.
Methods
Synthesis. the procedures for the synthesis of cyclic boronates are described in
Supplementary Methods. For NMR and MS analysis of the compounds in this
article, see Supplementary Figs 13–59.
Protein production and puriﬁcation. Recombinant forms of NDM-1, NDM-1
M67C, VIM-2, SPM-1, IMP-1, BcII, CphA, Tem-1, OXA-10, PBP 3 and PBP 5
were produced in E. coli as described9,10,23,28–30. Puriﬁed BcII, VIM-2, OXA-10
and PBP 5 proteins were separately dialysed into fresh crystallization buffer
(50mM HEPES pH 7.5, 150mM NaCl and 1 mg ZnCl2 for BcII and VIM-2 or
50mM MES pH 6.0, 100mM NaCl for OXA-10 or 50mM TRIS pH 7.5 and
500mM NaCl for PBP 5).
Crystallography. Crystals of BcII:2, VIM-2:2, OXA-10:1 and PBP5:2 were grown
using the conditions stated in Supplementary Table 2. Crystals were cryoprotected
using well solution diluted to 25% glycerol and harvested using nylon loops then
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ﬂash-cooled and stored in liquid nitrogen. Diffraction data for VIM-2:2 and
OXA-10:1 crystals were collected at the Diamond Light Source synchrotron
beamline I04, data for BcII:2 were collected using a Rigaku FREþ Superbright
diffractometer and data for PBP5:2 were collected at the Diamond Light Source
synchrotron beamline I02. All data sets were collected at 100K. Data for BcII,
VIM-2 and PBP 5 were indexed, integrated and scaled using HKL-2000 and for
OXA-10 with Mosﬂm and Scala, respectively31. All structures were solved by
molecular replacement using Phaser32 using the previosly published VIM-2
(PDB ID: 4BZ3)17, OXA-10 (PDB ID: 1K6R)22, BcII (PDB ID: 4C09)17 or PBP 5
(PDB ID: 1NZO) as search models for their respective data set. The structures were
then iteratively ﬁt and reﬁned using COOT33 and PHENIX31 until Rwork and Rfree
no longer converged. Data collection and reﬁnement statistics are given in
Supplementary Table 3.
Kinetic analyses. Kinetic and inhibition analyses, and 19F NMR studies10 against
bacterial b-lactamases were performed as described9. The FC-5 cephalosporin9 was
used as substrate for BcII, VIM-2, IMP-1, NDM-1, SPM-1, TEM-1 and OXA-10,
meropenem28 for CphA and nitroceﬁn34 for PBP 3 and PBP 5.
In brief IC50 values were determined by preincubation of the appropriate
amount of enzyme with the cyclic boronates in the assay buffers for 10min at room
temperature prior to the initiation of the assay by the addition of the appropriate
substrate. The enzyme concentrations used are the following: 1 nM BcII, 100 nM
VIM-2, 10 nM IMP-1, 10 nM NDM-1, 1 nM SPM-1, 1 nM TEM-1, 1 nM OXA-10,
2.5 nM CphA, 4 mM PBP 3 and 5 mM PBP 5; note that the ﬁnal concentrations are
stated. The assay buffers used are the following: 50mM HEPES, pH 7.2
supplemented with 1 mg BSA, 1 mg ZnSO4 and 0.01% Triton for BcII, VIM-2,
IMP-1, NDM-1 and SPM-1, 15mMMES, pH 6.5 for CphA, 50mM HEPES, pH 7.2
supplemented with 200mM NaCl and 0.01% Triton 100 for TEM-1, 100mM
sodium phosphate, pH 7.2 supplemented with 50mM NaHCO3 and 0.01%
Triton 100 for OXA-10 and 50mM HEPES, pH 7.2 supplemented with 200mM
NaCl and 0.01% Triton 100 for PBP 3 and PBP 5. The amount of substrates used is
the following: 5 mM for BcII, VIM-2, IMP-1, NDM-1 and SPM-1, 10 mM for
TEM-1 and OXA-10, 125 mM for CphA and 25mM for PBP 3 and PBP 5; note that
the ﬁnal concentrations are stated.
The experiments were performed using a PHERAstar FS microplate reader
(BMG Labtech) at room temperature (24–25 C). All enzymes and inhibitors
were prepared in the speciﬁc assay buffer. The kinetic values in this study are the
means from at least three independent measurements; at least nine different
concentrations of the inhibitor were used to determine the kinetic parameters
(IC50). The IC50 values were determined using the software package Graph Prism 5.
Cytotoxicity assay. HEK293 cells were seeded (2,000 per well) in normal DMEM
in 96-well plates.34 After 24 h, wells were dosed with titrated concentration of
compounds in 1% dimethyl sulphoxide (DMSO)—ﬁnal volume of media about
100ml. Following a further 24 h incubation period, 20 ml tetrazolium (MTS,
CellTiter96Aqueous One Solution (Promega)) was added to the media in each well.
The plate was incubated at 37 C, 5% CO2 for 4 h in the dark before absorbance was
read at 490 nm to determine cell proliferation values.
Microbiological susceptibility testing. Bacterial strains: E. coli ATCC 25922
(ref. 35) and K. pneumoniae NCTC 5055 (ref. 36) were used as reference strains.
K. pneumoniae Ecl8 (ref. 16) and its ramR knock-out37 were used as previously
described38,39. K. pneumoniae strain IR8 (ref. 40), and E. coli strains IR10 and IR60
(ref. 17) were generous gifts of Prof. T.R. Walsh. Plasmid pSU18:NDM-1 contains
the complete blaNDM-1 open reading frame, together with its promoter, cloned into
plasmid pSU18 (ref. 41). The recombinant plasmid was made by PCR amplifying
the blaNDM-1 gene and surrounding sequences from E. coli IR10 with primers
NDM1F 50-ACACCATTAGAGAAATTTGC-30 and NDM1R 50-GGCGATGAC
AGCATCATC-30 , TA cloning the amplicon into pCR2.1 TOPO (Invitrogen) and
subcloning into pSU18 using BamHI and XbaI.
MIC values were determined by broth microdilution, in triplicate, in
cation-adjusted Mueller Hinton broth (Sigma) according to the Clinical Laboratory
Standards Institute (CLSI) guidelines42. Experiments were carried out in microtitre
plates (Corning) containing the medium plus meropenem (Sequoia Research
Products, Pangbourne, UK) and/or inhibitor 2 as appropriate. Chloramphenicol
(20 mgml 1) was included in assays of strains (K. pneumoniae Ecl8 and derivative)
that carried pSU18 plasmids or derivatives (pSU18:NDM-1) to ensure maintenance
of plasmids throughout. Inhibitor 2 was dissolved in DMSO to 100mgml 1 and
diluted in broth. The ﬁnal concentration of DMSO in the assays was kept constant
at 0.01% (experiments using 10 mgml 1 inhibitor) or 0.03% (experiments using
25mgml 1 inhibitor). Plates were incubated overnight at 37 C for 18–24 h and
absorbance at 600 nm read using a Polarstar Omega (BMG LabTech) plate reader.
Data availability. Data supporting the ﬁndings of this study are available within
the article (and its Supplementary Information ﬁles) and from the corresponding
author upon reasonable request. Coordinates and structure factors have been
deposited in the Protein Data Bank under accession codes 5FQB (BcII-2), 5FQC
(VIM-2:2), 5FQ9 (OXA-10:1) and 5J8X (PBP 5:2).
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